ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
정신분열증 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년 연평균 성장률(CAGR)은 6.0%를 나타낼 것으로 예측되고 106억 1,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 더 나은 효과적인 치료 결과에 대한 수요 증가, 항정신병 약물 발전을 위한 연구 개발 활동 증가, 제품 출시 및 승인, 정신 건강 문제를 위한 신약 개발에 대한 투자 확대, 정신 건강 치료에 대한 보험 적용 범위 확대, 정부 주도 정책 및 지원 등에 기인할 수 있습니다. 예측 기간의 주요 트렌드로는 지속형 주사제 개발, 모바일 앱 및 웨어러블 기기와 같은 디지털 도구 도입, 글루타메이트 경로 표적 약물의 등장, 유전자 및 바이오마커 연구 활용, 보조 치료에 대한 관심 증대 등이 있습니다.
향후 5년간 6.0% 성장률 예측은 이 시장에 대한 이전 추정치 대비 0.4% 소폭 하락한 수치입니다. 이러한 감소는 주로 미국과 타국 간 관세 영향 때문입니다. 무역 분쟁으로 벨기에 및 아일랜드에서 수입되는 비정형 항정신병 약물과 장기작용 주사제 가격이 상승하여 미국 정신과 시설에 부담을 주고, 정신 건강 치료를 저해하며 행동 건강 관리 비용을 증가시킬 수 있습니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 세계 경제 및 무역에 대한 부정적 영향으로 그 효과가 더 광범위하게 나타날 것입니다.
정신분열증 환자 수 증가가 정신분열증 치료제 시장 성장을 견인할 것으로 예상됩니다. 정신분열증은 왜곡된 사고, 지각, 감정 및 행동을 특징으로 하는 만성 정신 질환으로, 종종 환각과 망상을 유발합니다. 유전적 소인, 환경적 스트레스 요인, 약물 남용, 뇌 화학 물질 불균형 등의 요인이 정신분열증 환자 증가에 기여하고 있습니다. 정신분열증 치료제는 증상을 관리하여 환자의 일상생활에 미치는 장애의 영향을 줄이고 전반적인 치료 결과를 개선하는 데 도움을 줍니다. 예를 들어, 2024년 2월 미국 국립의학도서관(National Library of Medicine)은 미국 인구의 정신분열증 및 관련 정신병적 장애 유병률이 0.25%에서 0.64% 사이로 보고했습니다. 또한 2024년 1월, 캐나다에 기반을 둔 비영리 단체인 브리티시컬럼비아 정신분열증 협회는 정신분열증이 정신 질환으로 인한 입원의 주요 원인이며, 일반 병원 입원의 19.9%, 정신과 병원 입원의 30.9%를 차지한다고 밝혔습니다. 결과적으로 증가하는 정신분열증 사례 수는 정신분열증 치료제 시장의 성장을 촉진할 것입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 정신분열증 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 정신분열병 치료제 시장 : 성장률 분석
세계의 정신분열증 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 정신분열증 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 정신분열증 치료제 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 정신 분열증 치료제 시장 : 치료 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제2세대
제3세대
기타 치료 클래스
세계의 정신분열증 치료제 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경구
주사제
세계의 정신분열증 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 정신 분열증 치료제 시장, 기타 치료 클래스 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제1세대 항정신병제
병용 요법
기타
제7장 지역별, 국가별 분석
세계의 정신분열증 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 정신분열증 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
정신분열증 치료제 시장 : 경쟁 구도
정신분열증 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol Myers Squibb
AstraZeneca PLC
Eli Lilly and Company
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Teva Pharmaceutical Industries Ltd.
UCB SA
Sun Pharmaceutical Industries Ltd.
AbbVie Inc.
H. Lundbeck A/S
Cipla Ltd.
Lupin Limited
Alkermes plc
Vanda Pharmaceuticals Inc.
Sumitomo Pharma Co. Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
정신분열증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
정신분열증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
정신분열증 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Schizophrenia medications are designed to alleviate the symptoms of schizophrenia, a chronic mental disorder that impacts thoughts, perceptions, emotions, and social interactions. These drugs work by addressing chemical imbalances in the brain, particularly those involving dopamine and serotonin, which helps reduce psychotic symptoms, stabilize mood, and improve cognitive abilities, leading to better daily functioning and increased independence.
The primary therapeutic categories of schizophrenia drugs include second-generation, third-generation, and other types. Second-generation antipsychotics, also known as atypical antipsychotics, treat schizophrenia by targeting dopamine and serotonin receptors. These drugs provide symptom relief with a reduced risk of movement disorders compared to first-generation antipsychotics. They are available in various forms, such as oral and injectable, and are distributed through multiple channels, including hospital pharmacies, retail pharmacies, online pharmacies, and other outlets.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The schizophrenia drugs market research report is one of a series of new reports from The Business Research Company that provides schizophrenia drugs market statistics, including the schizophrenia drugs industry global market size, regional shares, competitors with the schizophrenia drugs market share, detailed schizophrenia drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the schizophrenia drugs industry. These schizophrenia drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The schizophrenia drugs market size has grown strongly in recent years. It will grow from $7.96 billion in 2024 to $8.41 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to the emergence of newer drugs such as second and third-generation antipsychotics, an increase in the prevalence of mental disturbances and schizophrenia, a rise in awareness about mental health, a surge in mental health awareness programs by government and non-government organizations, rise in the number of geriatric populations.
The schizophrenia drugs market size is expected to see strong growth in the next few years. It will grow to $10.61 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to the increasing need for better and effective treatment outcomes, increase in research and development activity for advancements in antipsychotic drugs, product launches, and product approvals, growing investments in the development of novel pharmaceuticals for mental health issues, better insurance coverage for mental health treatments, government initiatives, and support. Major trends in the forecast period include the development of long-acting injectable formulations, the introduction of digital tools, such as mobile apps and wearables, the emergence of drugs targeting glutamatergic pathways, utilization of genetic and biomarker research, and a growing focus on adjunct therapies.
The forecast of 6.0% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade disputes may burden U.S. psychiatric facilities by increasing prices of atypical antipsychotics and long-acting injectable formulations imported from Belgium and Ireland, potentially compromising mental health treatment and raising behavioral healthcare costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing number of schizophrenia cases is expected to drive the growth of the schizophrenia drugs market. Schizophrenia is a chronic mental disorder characterized by distorted thoughts, perceptions, emotions, and behaviors, often leading to hallucinations and delusions. Factors such as genetic predisposition, environmental stressors, substance abuse, and imbalances in brain chemistry are contributing to the rise in schizophrenia cases. Schizophrenia medications help manage symptoms, reducing the disorder's impact on patients' daily lives and improving overall treatment outcomes. For example, in February 2024, the National Library of Medicine, a US-based biomedical library, reported that the prevalence of schizophrenia and related psychotic disorders in the US population ranged from 0.25% to 0.64%. Additionally, in January 2024, the British Columbia Schizophrenia Society, a nonprofit organization based in Canada, stated that schizophrenia is a leading cause of hospitalization for mental illnesses, accounting for 19.9% of general hospital admissions and 30.9% of psychiatric hospital stays. As a result, the increasing number of schizophrenia cases will fuel the growth of the schizophrenia drugs market.
Leading companies in the schizophrenia drugs market are focused on developing advanced treatments, such as oral medications for schizophrenia, to improve patient care and treatment outcomes. Oral medications for schizophrenia are taken by mouth to manage the symptoms of the disorder, typically involving antipsychotics that help stabilize mood, thoughts, and perceptions. For example, in September 2024, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved Cobenfy, an innovative oral medication for treating schizophrenia in adults. This groundbreaking drug combines xanomeline and trospium chloride, offering a new approach compared to traditional antipsychotics by targeting cholinergic receptors rather than dopamine receptors. This unique mechanism has the potential to alleviate symptoms such as delusions and disorganized thinking while minimizing the common side effects associated with older antipsychotic medications, making Cobenfy a promising alternative in schizophrenia treatment.
In March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, acquired Karuna Therapeutics for $14 billion. This acquisition is expected to enhance Bristol Myers Squibb's neuroscience portfolio by adding KarXT, a new antipsychotic, and expanding its pipeline with potential treatments for schizophrenia, Alzheimer's disease, and other mental health disorders. Karuna Therapeutics, a US-based biopharmaceutical company, specializes in producing drugs for schizophrenia.
Major players in the schizophrenia drugs market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co., Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., UCB S.A., Sun Pharmaceutical Industries Ltd., AbbVie Inc., H. Lundbeck A/S, Cipla Ltd., Lupin Limited, Alkermes plc, Vanda Pharmaceuticals Inc., Sumitomo Pharma Co. Ltd., Mylan NV, Otsuka Pharmaceutical Co. Ltd., Reviva Pharmaceuticals Holdings Inc., Lifegenix, and Flagship Biotech International Pvt. Ltd.
North America was the largest region in the schizophrenia drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in schizophrenia drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the schizophrenia drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The schizophrenia drugs market consists of sales of transdermal patches, liquid formulations, and adjunctive therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Schizophrenia Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on schizophrenia drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for schizophrenia drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The schizophrenia drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapeutic Class: Second Generation; Third Generation; Other Therapeutic Classes
2) By Treatment: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
Subsegments:
1) By Second Generation: Risperidone; Olanzapine; Quetiapine; Aripiprazole; Paliperidone; Ziprasidone; Others
2) By Third Generation: Brexpiprazole; Cariprazine; Others
3) By Other Therapeutic Classes: First-Generation Antipsychotics; Combination Therapies; Others
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Merck & Co.; Novartis AG; Sanofi S.A.; Bristol Myers Squibb; AstraZeneca PLC; Eli Lilly and Company; Amgen Inc.; F. Hoffmann-La Roche Ltd.; Teva Pharmaceutical Industries Ltd.; UCB S.A.; Sun Pharmaceutical Industries Ltd.; AbbVie Inc.; H. Lundbeck A/S; Cipla Ltd.; Lupin Limited; Alkermes plc; Vanda Pharmaceuticals Inc.; Sumitomo Pharma Co. Ltd.; Mylan NV; Otsuka Pharmaceutical Co. Ltd.; Reviva Pharmaceuticals Holdings Inc.; Lifegenix; Flagship Biotech International Pvt. Ltd.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Schizophrenia Drugs Market Characteristics
3. Schizophrenia Drugs Market Trends And Strategies
4. Schizophrenia Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Schizophrenia Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Schizophrenia Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Schizophrenia Drugs Market Growth Rate Analysis
5.4. Global Schizophrenia Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Schizophrenia Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Schizophrenia Drugs Total Addressable Market (TAM)
6. Schizophrenia Drugs Market Segmentation
6.1. Global Schizophrenia Drugs Market, Segmentation By Therapeutic Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Second Generation
Third Generation
Other Therapeutic Classes
6.2. Global Schizophrenia Drugs Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injectable
6.3. Global Schizophrenia Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Other Distribution Channels
6.4. Global Schizophrenia Drugs Market, Sub-Segmentation Of Second Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Risperidone
Olanzapine
Quetiapine
Aripiprazole
Paliperidone
Ziprasidone
Others
6.5. Global Schizophrenia Drugs Market, Sub-Segmentation Of Third Generation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Brexpiprazole
Cariprazine
Others
6.6. Global Schizophrenia Drugs Market, Sub-Segmentation Of Other Therapeutic Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Generation Antipsychotics
Combination Therapies
Others
7. Schizophrenia Drugs Market Regional And Country Analysis
7.1. Global Schizophrenia Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Schizophrenia Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
